miRNA levels are associated with body mass index in endometrial cancer and may have implications for therapy.
BMI
endometrial cancer
miRNA
obesity
personalized medicine
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
09 Jan 2024
09 Jan 2024
Historique:
revised:
07
09
2023
received:
06
07
2023
accepted:
13
09
2023
medline:
10
1
2024
pubmed:
10
1
2024
entrez:
10
1
2024
Statut:
aheadofprint
Résumé
Endometrial cancer (EC) is the most prevalent gynecological cancer in high-income countries. Its incidence is skyrocketing due to the increase in risk factors such as obesity, which represents a true pandemic. This study aimed to evaluate microRNA (miRNA) expression in obesity-related EC to identify potential associations between this specific cancer type and obesity. miRNA levels were analyzed in 84 EC patients stratified based on body mass index (BMI; ≥30 or <30) and nine noncancer women with obesity. The data were further tested in The Cancer Genome Atlas (TCGA) cohort, including 384 EC patients, 235 with BMI ≥30 and 149 with BMI <30. Prediction of miRNA targets and analysis of their expression were also performed to identify the potential epigenetic networks involved in obesity modulation. In the EC cohort, BMI ≥30 was significantly associated with 11 deregulated miRNAs. The topmost deregulated miRNAs were first analyzed in 84 EC samples by single miRNA assay and then tested in the TCGA dataset. This independent validation provided further confirmation about the significant difference of three miRNAs (miR-199a-5p, miR-449a, miR-449b-5p) in normal-weight EC patients versus EC patients with obesity, resulting significantly higher expressed in the latter. Moreover, the three miRNAs were significantly correlated with grade, histological type, and overall survival. Analysis of their target genes revealed that these miRNAs may regulate obesity-related pathways. In conclusion, we identified specific miRNAs associated with BMI that are potentially involved in modulating obesity-related pathways and that may provide novel implications for the clinical management of obese EC patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Union "NextGenerationEU"
ID : ALMA IDEA22 line A D.M. 737/2021
Organisme : European Union "NextGenerationEU"
ID : CUP J45F21002000
Organisme : Italian Ministry of Health
ID : RC22000684
Informations de copyright
© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412-1428.
James PT. Obesity: the worldwide epidemic. Clin Dermatol. 2004;22(4):276-280.
Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. 2019;145(7):1719-1730.
Gong TT, Wu QJ, Wang YL, Ma XX. Circulating adiponectin, leptin and adiponectin-leptin ratio and endometrial cancer risk: evidence from a meta-analysis of epidemiologic studies. Int J Cancer. 2015;137(8):1967-1978.
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-17.
Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016;3(1):1-12.
Wang Y, Zeng X, Tan J, Xu Y, Yi C. Diabetes mellitus and endometrial carcinoma: risk factors and etiological links. Medicine. 2022;101(34):E30299.
Wise MR, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. Am J Obstet Gynecol. 2016;214(6):689.e1-689.e17.
Renehan AG. Bariatric surgery, weight reduction, and cancer prevention. Lancet Oncol. 2009;10(7):640-641.
Luo J, Chlebowski RT, Hendryx M, et al. Intentional weight loss and endometrial cancer risk. J Clin Oncol. 2017;35(11):1189-1193.
Gallos ID, Ganesan R, Gupta JK. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet Gynecol. 2013;121(6):1165-1171.
Shaw E, Farris M, McNeil J, Friedenreich C. Obesity and endometrial cancer. Recent Results Cancer Res. 2016;208:107-136.
Papatla K, Huang M, Slomovitz B. The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population? Ann Oncol. 2016;27(11):1988-1994.
Zhan Y, Wang J, Ma Y, et al. Serum insulin-like, growth factor binding protein-related protein 1 (IGFBP-rP1) and endometrial cancer risk in Chinese women. Int J Cancer. 2013;132(2):411-416.
McGregor RA, Choi MS. microRNAs in the regulation of adipogenesis and obesity. Curr Mol Med. 2011;11(4):304-316.
Arner P, Kulyté A. MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinal. 2015;11:276-288.
Mori MA, Thomou T, Boucher J, et al. Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy. J Clin Invest. 2014;124(8):3339-3351.
Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol Mech Dis. 2014;9(1):287-314.
Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1(1):15004.
Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on gynecologic oncology. Int J Gynaecol Obstet. 2000;70(2):209-262.
Concin N, Planchamp F, Abu-Rustum NR, et al. European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. Int J Gynecol Cancer. 2021;31(12):1508-1529.
Ravegnini G, De Leo A, Coada C, et al. Identification of miR-499a-5p as a potential novel biomarker for risk stratification in endometrial cancer. Front Oncol. 2021;11:757678.
Schwarzenbach H, Da Silva AM, Calin G, Pantel K. Data normalization strategies for MicroRNA quantification. Clin Chem. 2015;61(11):1333-1342.
Getz G, Gabriel SB, Cibulskis K, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73.
Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71.
Giorgi FM, Ceraolo C, Mercatelli D. The R language: an engine for bioinformatics and data science. Life (Basel). 2022;12(5):648.
Deng M, Brägelmann J, Kryukov I, Saraiva-Agostinho N, Perner S. FirebrowseR: an R client to the Broad Institute's firehose pipeline. Database (Oxford). 2017;2017:baw160.
Bao J, Li D, Wang L, et al. MicroRNA-449 and MicroRNA-34b/c function redundantly in murine testes by targeting E2F transcription factor-retinoblastoma protein (E2F-pRb) pathway. J Biol Chem. 2012;287(26):21686-21698.
Ravegnini G, Gorini F, De Crescenzo E, et al. Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An Update Review. Int J Cancer. 2022;150(7):1077-1090.
Delangle R, De Foucher T, Larsen AK, et al. The use of microRNAs in the management of endometrial cancer: a meta-analysis. Cancers (Basel). 2019;11(6):832.
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk. Prev Treat. 2016;34(35):4225-4230.
Anderson B, Connor JP, Andrews JI, et al. Obesity and prognosis in endometrial cancer. Am J Obstet Gynecol. 1996;174(4):1171-1179.
Kajimoto K, Naraba H, Iwai N. MicroRNA and 3T3-L1 pre-adipocyte differentiation. RNA. 2006;12(9):1626-1632.
Gu N, You L, Shi C, et al. Expression of miR-199a-3p in human adipocytes is regulated by free fatty acids and adipokines. Mol Med Rep. 2016;14(2):1180-1186.
Song J, Gao L, Yang G, et al. MiR-199a regulates cell proliferation and survival by targeting FZD7. PLoS One. 2014;9(10):e110074.
Ahmadpour F, Nourbakhsh M, Razzaghy-Azar M, et al. The association of plasma levels of miR-34a and miR-149 with obesity and insulin resistance in obese children and adolescents. Acta Endocrinol (Buchar). 2018;14(2):149-154.
Fu T, Seok S, Choi S, et al. MicroRNA 34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte fibroblast growth factor 21 signaling and SIRT1 function. Mol Cell Biol. 2014;34(22):4130-4142.
Fu T, Choi S-E, Kim D-H, et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho. Proc Natl Acad Sci USA. 2012;109(40):16137-16142.
Jones PH, Deng B, Winkler J, et al. Over-expression of miR-34c leads to early-life visceral fat accumulation and insulin resistance. Sci Report. 2019;9(1):13844.
Ozcan L, Cristina De Souza J, Harari AA, Backs J, Olson EN, Tabas I. Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling. Cell Metab. 2013;18(6):803-815.
Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes. 2008;32(Suppl 4):S7-S12.
Song Z, Wang Y, Zhang F, Yao F, Sun C. Calcium signaling pathways: key pathways in the regulation of obesity. Int J Mol Sci. 2019;20(11):2768.
Pagano C, di Zazzo E, Avilia G, et al. Advances in “adiponcosis”: insights in the inner mechanisms at the base of adipose and tumour tissues interplay. Int J Cancer. 2023;152(12):2464-2473.
Wang ZV, Scherer PE. Adiponectin, the past two decades. J Mol Cell Biol. 2016;8(2):93-100.
Barr CE, Ryan NAJ, Derbyshire AE, et al. Weight loss during intrauterine progestin treatment for obesity-associated atypical hyperplasia and early-stage cancer of the endometrium. Cancer Prev Res (Phila). 2021;14(11):1041-1050.